Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that ...

Merck (NYSE:MRK) announced Wednesday that the U.S. Food and Drug Administration (FDA) granted priority review for its request ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck (MRK) ended the recent trading session at $80.93, demonstrating a -1.77% change from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.83%. At the same time, ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

The stock's fall snapped a four-day winning streak.

Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Merck's Winrevair gains FDA priority review for PAH label update after ZENITH trial shows major reduction in serious events and strong clinical impact.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...